Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Q1 2025 Management View CEO Dr. Albert Bourla discussed Pfizer's strategic focus on improving R&D productivity, emphasizing a disciplined approach to advancing its pipeline. The company highlighted ...

Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products from Seagen.

Please watch the video at Investors.com - How To Buy Stocks: Flat Base Chart Pattern Pfizer became a household name in ... called Paxlovid. The two products powered north of $100 billion in ...